{"drugs":["Proloprim","Trimethoprim","Trimpex"],"mono":{"0":{"id":"627445-s-0","title":"Generic Names","mono":"Trimethoprim"},"1":{"id":"627445-s-1","title":"Dosing and Indications","sub":[{"id":"627445-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>HIV infection - Pneumocystis pneumonia:<\/b> 15 mg\/kg\/day ORALLY in 3 divided doses, in combination with dapsone 100 mg ORALLY once daily for 21 days<\/li><li><b>Urinary tract infectious disease, Uncomplicated:<\/b> 100 mg ORALLY twice a day or 200 mg ORALLY once a day for 10 days; clinical guidelines recommend a dose of 100 mg ORALLY twice daily for 3 days for acute uncomplicated cystitis<\/li><\/ul>"},{"id":"627445-s-1-5","title":"Pediatric Dosing","mono":"trimethoprim tablet formulation not FDA-approved in children under 12 years of age"},{"id":"627445-s-1-6","title":"Dose Adjustments","mono":"<b>renal impairment:<\/b> CrCl 15-30 mL\/min, 50 mg every 12 hr; CrCl less than 15 mL\/min, not recommended"},{"id":"627445-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Urinary tract infectious disease, Uncomplicated<br\/><b>Non-FDA Labeled Indications<\/b><ul><li>Bacterial infection of eye<\/li><li>HIV infection - Pneumocystis pneumonia<\/li><\/ul>"}]},"3":{"id":"627445-s-3","title":"Contraindications\/Warnings","sub":[{"id":"627445-s-3-9","title":"Contraindications","mono":"<ul><li>hypersensitivity to trimethoprim products<\/li><li>megaloblastic anemia due to folate deficiency<\/li><\/ul>"},{"id":"627445-s-3-10","title":"Precautions","mono":"<ul><li>patients with possible folate deficiency<\/li><li>impaired hepatic or renal function<\/li><\/ul>"},{"id":"627445-s-3-11","title":"Pregnancy Category","mono":"<ul><li>C (FDA)<\/li><li>B3 (AUS)<\/li><\/ul>"},{"id":"627445-s-3-12","title":"Breast Feeding","mono":"<ul><li>AAP: Maternal medication usually compatible with breastfeeding.<\/li><li>WHO: Compatible with breastfeeding.  Monitor infant for side effects.<\/li><li>Micromedex: Infant risk is minimal.<\/li><\/ul>"}]},"4":{"id":"627445-s-4","title":"Drug Interactions","sub":[{"id":"627445-s-4-13","title":"Contraindicated","mono":"<ul><li>Dofetilide (probable)<\/li><li>Levomethadyl (theoretical)<\/li><\/ul>"},{"id":"627445-s-4-14","title":"Major","mono":"<ul><li>Acecainide (theoretical)<\/li><li>Ajmaline (probable)<\/li><li>Amiloride (theoretical)<\/li><li>Amiodarone (theoretical)<\/li><li>Amisulpride (theoretical)<\/li><li>Amitriptyline (probable)<\/li><li>Amoxapine (probable)<\/li><li>Aprindine (theoretical)<\/li><li>Arsenic Trioxide (theoretical)<\/li><li>Astemizole (theoretical)<\/li><li>Azathioprine (theoretical)<\/li><li>Azilsartan (theoretical)<\/li><li>Azilsartan Medoxomil (theoretical)<\/li><li>Azimilide (theoretical)<\/li><li>Benazepril (theoretical)<\/li><li>Bretylium (theoretical)<\/li><li>Candesartan Cilexetil (theoretical)<\/li><li>Captopril (theoretical)<\/li><li>Chloral Hydrate (theoretical)<\/li><li>Chloroquine (theoretical)<\/li><li>Chlorpromazine (theoretical)<\/li><li>Clarithromycin (theoretical)<\/li><li>Desipramine (probable)<\/li><li>Dibenzepin (probable)<\/li><li>Disopyramide (probable)<\/li><li>Dolasetron (theoretical)<\/li><li>Doxepin (probable)<\/li><li>Droperidol (theoretical)<\/li><li>Eltrombopag (theoretical)<\/li><li>Enalapril (theoretical)<\/li><li>Enalaprilat (theoretical)<\/li><li>Enflurane (theoretical)<\/li><li>Eplerenone (theoretical)<\/li><li>Eprosartan (theoretical)<\/li><li>Erythromycin (theoretical)<\/li><li>Flecainide (theoretical)<\/li><li>Fluconazole (theoretical)<\/li><li>Fluoxetine (theoretical)<\/li><li>Foscarnet (theoretical)<\/li><li>Fosinopril (theoretical)<\/li><li>Gemifloxacin (probable)<\/li><li>Halofantrine (theoretical)<\/li><li>Haloperidol (theoretical)<\/li><li>Halothane (theoretical)<\/li><li>Hydroquinidine (probable)<\/li><li>Ibutilide (theoretical)<\/li><li>Imipramine (probable)<\/li><li>Irbesartan (theoretical)<\/li><li>Isoflurane (theoretical)<\/li><li>Isradipine (theoretical)<\/li><li>Leucovorin (probable)<\/li><li>Lidoflazine (theoretical)<\/li><li>Lisinopril (theoretical)<\/li><li>Lorcainide (theoretical)<\/li><li>Losartan (theoretical)<\/li><li>Mefloquine (theoretical)<\/li><li>Mercaptopurine (theoretical)<\/li><li>Methotrexate (established)<\/li><li>Moexipril (theoretical)<\/li><li>Nortriptyline (probable)<\/li><li>Octreotide (theoretical)<\/li><li>Olmesartan Medoxomil (theoretical)<\/li><li>Pentamidine (theoretical)<\/li><li>Perindopril (theoretical)<\/li><li>Pirmenol (probable)<\/li><li>Prajmaline (probable)<\/li><li>Probucol (theoretical)<\/li><li>Procainamide (probable)<\/li><li>Prochlorperazine (theoretical)<\/li><li>Propafenone (theoretical)<\/li><li>Pyrimethamine (probable)<\/li><li>Quinapril (theoretical)<\/li><li>Quinidine (probable)<\/li><li>Ramipril (theoretical)<\/li><li>Risperidone (theoretical)<\/li><li>Sematilide (theoretical)<\/li><li>Sertindole (theoretical)<\/li><li>Sotalol (theoretical)<\/li><li>Spiramycin (theoretical)<\/li><li>Spironolactone (theoretical)<\/li><li>Sultopride (theoretical)<\/li><li>Tedisamil (theoretical)<\/li><li>Telithromycin (theoretical)<\/li><li>Telmisartan (theoretical)<\/li><li>Trandolapril (theoretical)<\/li><li>Triamterene (theoretical)<\/li><li>Trifluoperazine (theoretical)<\/li><li>Trimipramine (probable)<\/li><li>Valsartan (theoretical)<\/li><li>Vasopressin (theoretical)<\/li><li>Zofenopril (theoretical)<\/li><li>Zotepine (theoretical)<\/li><\/ul>"},{"id":"627445-s-4-15","title":"Moderate","mono":"<ul><li>Amantadine (probable)<\/li><li>Anisindione (probable)<\/li><li>Didanosine (probable)<\/li><li>Digoxin (probable)<\/li><li>Fosphenytoin (probable)<\/li><li>Phenytoin (probable)<\/li><li>Repaglinide (probable)<\/li><li>Rosiglitazone (established)<\/li><li>Tolbutamide (probable)<\/li><\/ul>"}]},"5":{"id":"627445-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Dermatologic:<\/b>Pruritus, Rash (2.9% to 6.7%)<br\/><b>Serious<\/b><ul><li><b>Dermatologic:<\/b>Erythema multiforme, Erythroderma, Stevens-Johnson syndrome, Toxic epidermal necrolysis<\/li><li><b>Immunologic:<\/b>Anaphylaxis<\/li><\/ul>"},"6":{"id":"627445-s-6","title":"Drug Name Info","sub":{"0":{"id":"627445-s-6-17","title":"US Trade Names","mono":"<ul><li>Proloprim<\/li><li>Trimpex<\/li><\/ul>"},"2":{"id":"627445-s-6-19","title":"Class","mono":"<ul><li>Antibiotic<\/li><li>Folic Acid Antagonist<\/li><\/ul>"},"3":{"id":"627445-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"627445-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"627445-s-7","title":"Mechanism Of Action","mono":"<ul><li>Systemic: Bacteriostatic lipophilic weak base structurally related to pyrimethamine, binds to and reversibly inhibits the bacterial enzyme dihydrofolate reductase, selectively blocking conversion of dihydrofolic acid to its functional form, tetrahydrofolic acid. This depletes folate, an essential cofactor in the biosynthesis of nucleic acids, resulting in interference with bacterial nucleic acid and protein production. Bacterial dihydrofolate reductase is approximately 50,000 to 60,000 times more tightly bound by trimethoprim than by the corresponding mammalian enzyme.<\/li><li>Exerts its effect at a step in the folate biosynthesis immediately subsequent to the one in which sulfonamides exert their effect. When administered concurrently with sulfonamides, synergism occurs and is attributed to inhibition of tetrahydrofolate production at two sequential steps in its biosynthesis.<\/li><\/ul>"},"8":{"id":"627445-s-8","title":"Pharmacokinetics","sub":[{"id":"627445-s-8-23","title":"Absorption","mono":"<ul><li>Systemic: Rapidly and almost completely (90 to 100%) absorbed from the gastrointestinal tract. <\/li><li>Rapid: 90 to 100%<\/li><\/ul>"},{"id":"627445-s-8-24","title":"Distribution","mono":"Systemic: Vd: 1.3 to 1.8 L\/kg Adults; 2.7 L\/kg Children; 1L\/kg Children (1 to 10 y old); Newborns: 2.7 L\/kg<br\/>"},{"id":"627445-s-8-25","title":"Metabolism","mono":"Systemic: Hepatic<br\/>"},{"id":"627445-s-8-26","title":"Excretion","mono":"Systemic: Renal: 50 to 60%;  Fecal: 4% <br\/>"},{"id":"627445-s-8-27","title":"Elimination Half Life","mono":"Systemic: 8 to 10 h Adults; 3 to 5.5 h Children (1 to 10 years); 19 h Newborns  <br\/>"}]},"10":{"id":"627445-s-10","title":"Monitoring","mono":"<ul><li>fever<\/li><li>CBC<\/li><li>symptomatic improvement<\/li><\/ul>"},"11":{"id":"627445-s-11","title":"How Supplied","mono":"<b>Generic<\/b><br\/>Oral Tablet: 100 MG<br\/>"},"12":{"id":"627445-s-12","title":"Toxicology","sub":[{"id":"627445-s-12-31","title":"Clinical Effects","mono":"<b>TRIMETHOPRIM<\/b><br\/>OVERDOSE: ACUTE: Following an overdose of 1 gram or more of trimethoprim, effects may include: nausea, vomiting, dizziness, headaches, depressed consciousness, confusion, and bone marrow suppression. ADVERSE EVENTS: COMMON: Rash and pruritus. Other effects have included: Nausea and vomiting, glossitis, epigastric distress, hyperkalemia, hyponatremia, thrombocytopenia, leukopenia, neutropenia, megaloblastic anemia, and methemoglobinemia. RARE: Exfoliative dermatitis, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, anaphylaxis, cholestatic jaundice and aseptic meningitis have occurred. CHRONIC: High dose therapy and\/or extended use may cause bone marrow depression manifested as thrombocytopenia, leukopenia, and megaloblastic anemia. OPHTHALMIC PREPARATIONS: Significant toxicity is NOT expected to occur following acute ingestion or topical application of ophthalmic preparations containing trimethoprim. Local irritation consisting of redness, burning, stinging, and\/or itching have been reported following the use of trimethoprim\/polymyxin B sulfate ophthalmic solution.<br\/>"},{"id":"627445-s-12-32","title":"Treatment","mono":"<b>TRIMETHOPRIM<\/b><br\/><ul><li>Decontamination: Consider activated charcoal if airway is protected. Irrigate exposed eyes.<\/li><li>Support: Treatment is symptomatic and supportive. There is no specific antidote following overdose.<\/li><li>Myelosuppression: Monitor CBC with differential. Administer leucovorin\/folinic acid at 5 to 15 mg orally daily to minimize hematologic toxicity. For severe neutropenia, administer colony stimulating factor. Filgrastim 5 mcg\/kg\/day subQ or IV over 15 to 30 minutes. Sargramostim 250 mcg\/meter(2)\/day IV over 4 hours. Transfusion of platelets and\/or packed red cells may be needed in patients with severe thrombocytopenia, anemia or hemorrhage.<\/li><li>Monitoring of patient: Monitor fluid and electrolyte status including sodium and potassium after acute overdose and in patients with severe vomiting. Monitor serial CBC with differential and platelet count in symptomatic patients. Monitor hepatic enzymes and renal function after significant overdose.<\/li><\/ul>"},{"id":"627445-s-12-33","title":"Range of Toxicity","mono":"<b>TRIMETHOPRIM<\/b><br\/>TOXICITY: Following an overdose of 1 gram or more of trimethoprim, effects may include: nausea, vomiting, dizziness, headaches, depressed consciousness, confusion, and bone marrow suppression. THERAPEUTIC DOSE: ORAL - TRIMETHOPRIM ALONE - ADULT: Treatment of uncomplicated urinary tract infections - 100 mg every 12 hours for 10 days, or 200 mg once daily for 10 days. PEDIATRIC: The effectiveness of trimethoprim as a single agent in children under 12 years has not been established. OPHTHALMIC - TRIMETHOPRIM\/POLYMYXIN B SULFATE - Instill 1 drop in the affected eye(s) every 3 hours (maximum of 6 doses\/day) for 7 to 10 days. <br\/>"}]},"13":{"id":"627445-s-13","title":"Clinical Teaching","mono":"<ul><li>May cause rash or pruritus.<\/li><li>Advise patient to take drug with food to minimize gastric irritation.<\/li><\/ul>"}}}